Biocon Biologics' new mAbs drug substance facility undergoes HPRA's GMP inspection
The inspection report contains no 'critical' observations and only one of the deficiencies is categorized as 'major' which is being addressed expeditiously in consultation with the regulatory agency
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content